// App-Quantinova.ai

2118 : Achieving Increasingly Stringent Clinical Disease Control Criteria Is Associated with Greater Improvements in Patient-Centric Measures of Physical Function and Pain in Patients with Active PsA: 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies

Researchers

Presenter

  • Jessica Walsh

Principal Investigators

  • Laura Coates

  • Philip J Mease

  • Joseph Merola

  • Peter Nash

  • Alexis Ogdie

  • William Tillett

  • Paolo Gisondi

  • Barbara Ink

  • Deepak Assudani

  • Rajan Bajracharya

  • Jérémy Lambert

  • Vanessa Taieb

  • Damon Willems

  • Lars Erik

Medical Centers

  • University of Utah, Salt Lake City, UT

  • Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences,, Oxford University Hospitals NHS Trust, Oxford, UK, Oxford, United Kingdom

  • Swedish Medical Center/Providence St. Joseph Health, Seattle, WA

  • Brigham and Women's Hospital and Harvard Medical School, Boston, MA

  • School of Medicine, Griffith University, QLD, Australia, Brisbane, Australia

  • Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

  • Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom

  • Dermatology and Venereology, Department of Medicine, Università di Verona, Verona, Italy, Verona

  • UCB Pharma, Slough, UK Slough United Kingdom

  • UCB Pharma, Colombes, France, Irigny, France

  • UCB Pharma, Colombes, France

  • UCB Pharma, Brussels, Belgium

  • Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark

Locations

  • United States

  • United Kingdom

  • Australia

  • Italy

  • France

  • Belgium

  • Denmark

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriatic arthritis

  • Psoriasis

Biomarkers

  • Albumin/creatinine

Drug/Treatment

  • bimekizumab

  • Adalimumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • III

Study Id's

  • NCT03895203

  • NCT03896581

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved